OMDA · Omada Health, Inc.

Current Thesis

Omada Health’s GLP-1 companion-care re-rating thesis has failed its published price test: the 2026-09-18 weekly close of $20.43 breached the $22 threshold established in the September 5 research. The operating story remains distinguishable from that market outcome: management presented long-term financial targets on September 10, but the subsequent reference close remains below the prior invalidation level.

For the previously published re-rating leg, the narrative is dead — the September 18 close establishes the structural break after the September 10 Investor Day. This classification is an inference about that specific market thesis, not a finding that Omada’s services or business have failed. The $22 threshold remains unchanged; lowering it after the breach would erase the published test.

Bullish and bearish views on Omada Health, Inc.

The model's bull view on Omada Health, Inc. (OMDA), in brief: Operating growth remains documented. Omada’s August 6 results reported second-quarter 2026 revenue of $87.835 million, up 43% year over year, and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $11 million. Those reported results support the… The bear view: The published threshold has failed. The adjusted September 18 close of $20.43 is below the September 5 dossier’s $22 weekly-close condition. The previous thesis is invalidated on price without needing to infer why market participants reduced their valuation. Long-term targets… Both cases follow in full.

Bull Case

• Operating growth remains documented. Omada’s August 6 results reported second-quarter 2026 revenue of $87.835 million, up 43% year over year, and adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) of $11 million. Those reported results support the operating case despite the September 18 price failure. Second-quarter results
• Investor Day supplied financial targets. On September 10, management announced long-term annual revenue growth of at least 20%, non-GAAP gross margin of 80%, and adjusted EBITDA margin of 30%. These are management objectives, rather than achieved results; subsequent reported growth below that annual floor would contradict the growth objective. Investor Day release

Bear Case

• The published threshold has failed. The adjusted September 18 close of $20.43 is below the September 5 dossier’s $22 weekly-close condition. The previous thesis is invalidated on price without needing to infer why market participants reduced their valuation.
• Long-term targets leave timing unresolved. The September 10 release does not specify an attainment year for its margin targets or a dated revenue contribution from GLP-1 prescribing, Flex Care or the cholesterol program. That release therefore does not settle the product-ramp question raised in the September 5 note; it also does not establish what every presentation or discussion disclosed. Investor Day release
• Analyst support did not restore structure. Benzinga headlines dated September 11, reproduced by MarketWall, reported Barclays raising its target to $27, with Needham maintaining $28 and BTIG maintaining $35. The September 18 reference close nevertheless remained below $22. These are observable coverage actions, not evidence of investor inflows. Dated analyst headlines

Setup & Price Structure

The supplied adjusted daily series records a September 18 close of $20.43, 23.7% below the $26.78 trailing-year high, with a three-month price increase of 13.6%. Its 14-period relative strength index (RSI) was 33.8. A positive three-month change does not reverse the observed breach of the previously published $22 threshold.

The September 4 reference close was $22.77 in the previous dossier. The later September 18 observation establishes further deterioration, but these snapshots do not identify the first breach date or isolate the Investor Day’s causal effect. No moving-average value, trading-volume series or current short-interest figure is available in the supplied evidence, so distance from trend and positioning concentration cannot be quantified. The September 11 analyst-headline cluster establishes coverage activity only; the sample is too small to support a retail-crowding claim.

Catalyst Calendar (next 30 days)

• 2026-09-20 through 2026-10-20: No company-confirmed upcoming event was identified for this window. The available company calendar lists September 10 Investor Day among past events and supplies no upcoming date. The next quarterly earnings date remains unconfirmed; September 10 is no longer an outstanding catalyst. Company event calendar

What Would Change Our Mind

The loss of the published $22 threshold has already broken the prior market thesis: a weekly close below $22 is the condition, and September 18’s $20.43 close satisfies it. A later weekly close above $22 would provide evidence of structural repair, but would not undo this recorded invalidation.

A separate operating reassessment would turn on subsequent reported revenue and management’s annual outlook. The August 6 release placed fiscal 2026 revenue guidance at $334–340 million; an explicit reduction below that range would weaken the operating case independently of the completed price breach. A dated, quantified product contribution would resolve more of the expansion question than the September 10 release’s long-term margin objectives alone. August 6 guidance

Correlation Notes

This remains a single-company assessment. The September 18 evidence contains no matched peer or index return series, so no measured correlation with healthcare, software or obesity-drug equities can be stated.

The connection to GLP-1 medicines is operational: the September 5 published research described companion care and prescribing as parts of Omada’s expansion thesis. That relationship does not establish that OMDA shares move with drug manufacturers. The September 10 company targets and September 18 price breach are sufficient to assess this particular narrative without attributing the move to a sector factor.